Cannabis Use Registry to Improve Overall Understanding of Symptoms (CURIOUS) (CURIOUS)

November 10, 2025 updated by: HealthPartners Institute
Through partnership with Ontracka, the HealthPartners Institute Cancer Research Center created a secure and compliant app-based technology with the ability to seamlessly collect patient-level data on symptoms, cannabis use, real-time response to cannabis consumption, and patient-reported changes in supportive care medications such as opioids and antiemetics. By joining this registry, patients will have access to expert cannabis education, dosing recommendations, and easy symptom tracking. Patients with cancer and their oncology clinicians can utilize this reliable, cancer-specific data to help them make informed decisions together about how cannabis could be incorporated into a treatment plan. To learn more and sign up, visit https://study.ontracka.com/cannabiscurious

Study Overview

Status

Recruiting

Conditions

Detailed Description

The CURIOUS project enhances the ability to seamlessly collect patient-level data on symptoms, cannabis use, real-time response to cannabis consumption, and patient-reported changes in supportive care medications such as opioids and antiemetics. Any patient interested in cannabis use can access the weblink to receive information about the CURIOUS study. An electronic version of the informed consent document will be available for them to review.

Patients interested in participating in the CURIOUS study will sign an electronic consent form on the app that describes how data will be used and stored by the HealthPartners and the Ontracka teams. They will be required to submit their name, email, and date of birth. This will automatically establish an account in the OnTracka platform and provide instruction on how to download and install the OnTracka mobile app. After patients consent to participate, they will receive access to the Ontracka app to track cannabis consumption and symptom responses as well as complete embedded validated questionnaires sent to them through the app at defined intervals; NCI PRO-CTCAE (PRO) (every other week), PROMIS Global (QOL) (every 4 weeks) and medication logs (every 4 weeks) through 12 weeks. After week 12 collection, they will complete all surveys once again in month 6 and month 12.

Study Type

Observational

Enrollment (Estimated)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Minnesota
      • Saint Louis Park, Minnesota, United States, 55426
        • Recruiting
        • HealthPartners Institute Cancer Research Center
        • Principal Investigator:
          • Dylan Zylla, MD, MS
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

any adult aged 18 or older who is diagnosed with cancer and using cannabis

Description

Inclusion Criteria:

  • any adult aged 18 or older who is diagnosed with cancer and using cannabis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adherence
Time Frame: from enrollment to the first 90 days of study participation
Assess adherence to CURIOUS platform by determining the percentage of consented patients who access the app/survey at least once per month during the first 90 days.
from enrollment to the first 90 days of study participation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

HealthPartners Institute

Collaborators

Ontracka

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 26, 2025

Primary Completion (Estimated)

April 1, 2027

Study Completion (Estimated)

April 1, 2028

Study Registration Dates

First Submitted

November 10, 2025

First Submitted That Met QC Criteria

November 10, 2025

First Posted (Actual)

November 12, 2025

Study Record Updates

Last Update Posted (Actual)

November 12, 2025

Last Update Submitted That Met QC Criteria

November 10, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • A24-181

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe